In the present study, bone marrow SMAD-7 expression levels were found to be suppressed in patients with low-risk MDS at diagnosis, while TGF-β1 expression was moderate to strong in approximately one-third (32.1%) of patients. This evidence concerns the gene TGFB1 and myelodysplastic syndrome.